The goal of this proposal is to elucidate the physiological role of the novel adaptor protein HSH2 (JHematopoietic SH2 protein) in regulation of B lymphocyte biology. Studies conducted in our laboratory have demonstrated that HSH2 is expressed at low basal levels in splenic B cells and that its expression is induced in response to stimuli that bind to distinct families of receptors that promote survival and differentiation, including CD40L, IL-4, LPS, CpG DMA and BLyS (BAFF). Up-regulation of HSH2 expression was shown to be dependent on activation of NF-icB and correlates with initiation of a survival responsethat includes up-.regulation of Bcl-Xi.. Retroviral-mediated expression of HSH2 in the WEHI-231 B cell line, which undergoes apoptosis in response to BCR ligation, was observed to enhance survival and mitochondrial stability. Similarly, enhanced survival of WEHI-231 cells in response to CD40-mediated signaling directly correlated with up-regulation of HSH2 expression. Although HSH2 does not significantly alter BCR-proximal signal transduction, it was observed to maintain mitochondrial stability and this correlated with its ability to block up-regulation of Bim in response to BCR signaling. Moreover, HSH2 was found to interact with the anti-apoptotic protein HAX-1, which possessesa membrane-spanning region that targets it to the outer mitochondrial membrane. Preliminary studies have shown that the interaction between HSH2 and HAX-1 is important for the anti-apoptotic activity of HSH2. Therefore, HSH2 and HAX-1 may function together to regulate mitochondrial integrity and cell survival. To further elucidate the physiological role of HSH2 in regulation of B lymphocyte survival/differentiation, three specific aims have been proposed that will: 1) determine the physiological role of HSH2 in B lymphocyte development, homeostasis and immune function; 2) elucidate the role that HSH2 plays in regulating Bim expression in response to co-stimulation; and 3) determine the functional importance of the interaction between HSH2 and HAX-1 in regulating mitochondrial stability. Because HSH2 expression is induced in response to many of the key stimuli that are known to promote B cell survival and differentiation, this adaptor protein is likely to play an important role in regulating B cell homeostasis and immune function. Therefore, these studies will provide novel insight into the molecular mechanisms that maintain the balance between B lymphocyte survival and death leading to differentiation into humoral effector cells and will provide insight into the etiology and progression of diseases associated with aberrant B cell function, including cancer and autoimmunity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
3R01AI072647-02S1
Application #
7612425
Study Section
Special Emphasis Panel (ZRG1-IMM-B (03))
Program Officer
Ferguson, Stacy E
Project Start
2008-04-23
Project End
2012-02-29
Budget Start
2008-04-23
Budget End
2009-02-28
Support Year
2
Fiscal Year
2008
Total Cost
$67,141
Indirect Cost
Name
University of Alabama Birmingham
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
King, R Glenn; Herrin, Brantley R; Justement, Louis B (2011) Differential expression of the adaptor protein HSH2 controls the quantitative and qualitative nature of the humoral response. J Immunol 187:3565-77
Bartlett, M S; Queener, S F; Shaw, M M et al. (1997) In vitro and in vivo models of Pneumocystis carinii. J Eukaryot Microbiol 44:51S
Furlong, S T; Koziel, H; Bartlett, M S et al. (1997) Lipid transfer from human epithelial cells to Pneumocystis carinii in vitro. J Infect Dis 175:661-8
Lane, B R; Ast, J C; Hossler, P A et al. (1997) Dihydropteroate synthase polymorphisms in Pneumocystis carinii. J Infect Dis 175:482-5
Bartlett, M S; Current, W L; Goheen, M P et al. (1996) Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 40:1811-6
Bartlett, M S; Shaw, M; Navaran, P et al. (1995) Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Antimicrob Agents Chemother 39:2436-41
Ittarat, I; Asawamahasakda, W; Bartlett, M S et al. (1995) Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother 39:325-8
Queener, S F (1995) New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. J Med Chem 38:4739-59
Hong, Y L; Bartlett, M S; Queener, S et al. (1995) Pteroylpolyglutamate synthesis by lung- and culture-derived Pneumocystis carinii. FEMS Microbiol Lett 134:251-4
Lu, J J; Bartlett, M S; Shaw, M M et al. (1994) Typing of Pneumocystis carinii strains that infect humans based on nucleotide sequence variations of internal transcribed spacers of rRNA genes. J Eukaryot Microbiol 41:102S

Showing the most recent 10 out of 48 publications